SCHEMBL16626781

SCHEMBL16626781

CNCc1cn(S(=O)(=O)c2cccc(F)c2)c2cc(Nc3ccc(F)cc3C)ncc12

nearest known ligand 0.41

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 9/20 0.41
PIK3CA P42336 1/20 0.40
PRKDC P78527 1/20 0.40
DRD2 P14416 1/20 0.38
BRD4 O60885 1/20 0.37
PTGDR Q13258 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
HTR2A P28223 1/20 0.34
IDE P14735 1/20 0.34
SLC6A4 P31645 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16619325 0.99 HTR6 (0.40) HTR6PIK3CAPRKDCDRD2BRD4
SCHEMBL16626668 0.90 HTR6 (0.40) HTR6DRD2BRD4IDE
Hydrochloric Acid SCHEMBL16618810 0.90 HTR6 (0.41) HTR6DRD2BRD4HTR2AIDE
SCHEMBL16626797 0.88 HTR6 (0.39) HTR6DRD2BRD4HTR2AIDE
Hydrochloric Acid SCHEMBL16619085 0.88 HTR6 (0.38) HTR6DRD2BRD4HTR2AIDE
SCHEMBL17971595 0.88 HTR6 (0.38) HTR6DRD2BRD4HTR2AIDE
Hydrochloric Acid SCHEMBL16619779 0.87 HTR6 (0.38) HTR6DRD2BRD4HTR2AIDE
SCHEMBL16626788 0.86 HTR6 (0.39) HTR6DRD2BRD4HTR2AIDE
Hydrochloric Acid SCHEMBL16619073 0.86 HTR6 (0.38) HTR6DRD2BRD4HTR2AIDE
SCHEMBL17971594 0.85 HTR6 (0.47) HTR6PIK3CADRD2HTR2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP claimed
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME GIPR, PGC, SI HTR6 166/4885PIK3CA 3089/4885PRKDC 3149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.